Cargando…
MITF is a driver oncogene and potential therapeutic target in kidney angiomyolipoma tumors through transcriptional regulation of CYR61
Tuberous sclerosis complex (TSC) is an autosomal dominant tumor suppressor syndrome, characterized by tumor development in multiple organs, including renal angiomyolipoma. Biallelic loss of TSC1 or TSC2 is a known genetic driver of angiomyolipoma development, however whether an altered transcription...
Autores principales: | Zarei, Mahsa, Giannikou, Krinio, Du, Heng, Liu, Heng-Jia, Duarte, Melissa, Johnson, Sneha, Nassar, Amin H., Widlund, Hans R., Henske, Elizabeth P., Long, Henry W., Kwiatkowski, David J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796905/ https://www.ncbi.nlm.nih.gov/pubmed/33082558 http://dx.doi.org/10.1038/s41388-020-01504-8 |
Ejemplares similares
-
Tumors with TSC mutations are sensitive to CDK7 inhibition through NRF2 and glutathione depletion
por: Zarei, Mahsa, et al.
Publicado: (2019) -
Whole Exome Sequencing Identifies TSC1/TSC2 Biallelic Loss as the Primary and Sufficient Driver Event for Renal Angiomyolipoma Development
por: Giannikou, Krinio, et al.
Publicado: (2016) -
The Roles of CCN1/CYR61 in Pulmonary Diseases
por: Zhu, Yin, et al.
Publicado: (2020) -
Cyr61 Expression is associated with prognosis in patients with colorectal cancer
por: Jeong, Dongjun, et al.
Publicado: (2014) -
Cyr61: a potential therapeutic target for prostate cancer
por: Lin, Chang-Ming, et al.
Publicado: (2014)